What the FDA labels say about taking them together
Pretomanid and valsartan
Pretomanid's FDA label of November 15, 2024 names valsartan in its drug interactions section; the valsartan labels PlainMeds reads (2) do not name pretomanid. The pretomanid label: “Therefore, it cannot be excluded that co-administration of pretomanid with sensitive OATP1B3 substrates (e.g., valsartan, statins), BCRP substrates and P-gp substrates may increase their exposure.”
Check it at the source: the pretomanid FDA label on DailyMed (effective November 15, 2024, Viatris Specialty LLC); the valsartan FDA label on DailyMed (effective August 5, 2026, Macleods Pharmaceuticals Limited).
What does the pretomanid label say about valsartan?
Pretomanid label, drug interactionsTherefore, it cannot be excluded that co-administration of pretomanid with sensitive OATP1B3 substrates (e.g., valsartan, statins), BCRP substrates (e.g., rosuvastatin, prazosin, glyburide, sulfasalazine) and P-gp substrates (e.g., digoxin, dabigatran etexilate, verapamil) may increase their exposure.
Source: FDA drug label (Pretomanid), NDA212862 (Mylan Ireland Ltd), as published by Viatris Specialty LLC, effective November 15, 2024 (SPL set f1906fc9-cb3c-4e13-8a4a-da76100c1bf3), via openFDA; the full label on DailyMed
What does the valsartan label say about pretomanid?
Valsartan's label (effective August 5, 2026) and its 1 other brand-application label do not name pretomanid in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Valsartan), Macleods Pharmaceuticals Limited, effective August 5, 2026 (SPL set 251ccff4-bf86-453b-9d1c-e3c1ecfd3a46), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Pretomanid | Valsartan | |
|---|---|---|
| Labeled for | n/a | High blood pressure, Heart failure |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | n/a | $0.0963 per tablet 40 mg tablet |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once